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Received 20 June 2017; revised 29 July 2017; accepted 4 August 2017AbstractVestibular schwannoma (VS) is a slow-growing benign neoplasm. There has been an evolution in the management of VS from active
treatments (microsurgery and stereotactic radiotherapy) to conservative management (wait and scan). Regular MRI scanning is necessary to
monitor tumor progression. Conservative management causes significantly less complications and offers a higher quality of life compared with
active treatments. The mean growth rate of VS varies from 0.4 to 2.9 mm/year, and spontaneous shrinkage is observed in 3.8 percent of tumors
during observation. If significant growth occurs, active treatment is considered. Significant growth is defined as an increase of at least 3 mm in
the largest extrameatal diameter in any plane between the first and last available scans. The vestibulocochlear nerve is surrounded by cere-
brospinal fluid, which provides natural contrast for MRI; thus, gadolinium may not be needed to detect VS. Specific sequences have high
sensitivity, specificity, and accuracy for detection of progression. Hypointense signal in the ipsilateral inner ear fluid might be a useful sign to
distinguish VS from meningioma. In this paper, we summarize the current status of research on conservative management and non-contrast MRI
for the detection of VS.
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Vestibular schwannomas (VSs) are benign neoplasms of the
8th cranial nerve originating from the myelin-forming Schwann
cells of either the superior (SVN) or inferior vestibular nerve
(IVN), and the latter accounts for more than 90% of cases
(Khrais et al., 2008). Patients with VSs commonly complain of
asymmetric hearing loss that may be accompanied by tinnitus,
dizziness, facial numbness or weakness, or a combination of
these. The VS is the most common cerebellopontine angle
tumor with a proportion of approximately 80e90% and it ac-
counts for 8e10% of all intracranial neoplasms (Tallan et al.,
1993; Valvassori, 1988). The VS has an estimated annual inci-
dence of 1.09 per 100,000 population inUSA and 2.55e3.32 per
100,000 population in Netherlands (Kleijwegt et al., 2016;
Kshettry et al., 2015). However, this number is significantly
higher in Denmark, where the annual incidence has risen from
78 per 100,000 in 1976 to 230 per 100,000 in 2004 likely due to
improved detection with magnetic resonance imaging (MRI)
(Stangerup and Caye-Thomasen, 2012). In addition, tumor size
at diagnosis has decreased significantly over time, probably due
to same reason. The current trend in treatment is from traditional
microsurgical resection or stereotactic radiotherapy to conser-
vativemanagement (it is also called wait and scan) (Fayad et al.,
2014; Jufas et al., 2015; Lee et al., 2014; Patnaik et al., 2015;
Rosenberg, 2000; Stangerup and Caye-Thomasen, 2012; Stan-
gerup et al., 2008). For the “wait and scan” strategy, non-
contrast MRI has the advantage of avoiding exposure to the
contrast agent of gadolinium chelate in either screening or
follow-up ofVS, but still providing reliable results with constant
improvements in technique (Oh et al., 2013; Ozgen et al., 2009;
Schulze et al., 2016). This is important for the patients who need
serial imaging. This review will present the recent progress in
conservative management and non-contrast MRI in the treat-
ment of VS.
2. The biological behavior of vestibular schwannoma
VSs can be either bilateral (neurofibromatosis 2, NF2) or
unilateral (sporadic VSs), in which the NF2-associated VSstend to be more aggressive than the sporadic VSs (Linthicum
and Brackmann, 1980) although the latter one may also
sparsely exhibit aggressive behavior (Feghali and Kantrowitz,
1995). Inactivation of the NF2 gene, that leads to a loss of
merlin (schwannomin, a putative tumor suppressor) expres-
sion, is believed to be paramount to the pathogenesis of both
NF2 and sporadic VSs (Zwarthoff, 1996). The involvement of
merlin depletion in the schwannoma tumorigenesis induces
deregulation of ErbB receptor signaling, promoting a dedif-
ferentiated state, and increasing Schwann cell proliferation
(Ahmad et al., 2010). Expressed merlin may also be phos-
phorylated at the site of S518 by members of the PAK family
of kinase and thus failed to enter the nucleus of Schwann cells
of VS at S phase that is opposite to the wild type merlin (Lu
et al., 2008). The ratio of merlin and S518 phosphorylated
merlin may contribute to the biological behavior of VS with
respect to the growth rate.
In general, VSs grow very slowly but variably with the
average annual tumor growth rate varying from 0.4 to
2.9 mm/y (Yoshimoto, 2005). Even spontaneous shrinkage
was observed in 3.8 percent of tumors during the “wait and
scan” period (Huang et al., 2013). The variability may be
associated with the clinical parameters selected, limited
number of patients, different observation periods, location of
the tumor, and gene status. Intratumoral hemorrhage, vessel
density, the inflammatory reaction, and M2-polarized mac-
rophages associated angiogenesis contribute to volume in-
crease of sporadic vestibular schwannomas (Caye-Thomasen
et al., 2005; de Vries et al., 2012; de Vries et al., 2013;
Koutsimpelas et al., 2007). The VSs usually cause expan-
sion of the internal auditory meatus within the temporal bone
due to the growth. It is generally believed that the size and
location of the tumor are the prime determinants of the extent
of internal auditory meatus bone remodeling and expansion.
Tumors that arise laterally along the course of the vestibular
nerve tend to cause more expansion of the internal auditory
meatus than those that arise more medially which can grow
towards the cerebellopontine angle cistern. Due to this, large
VSs may compress the brainstem, and an active intervention
is needed.
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for the most pronounced negative impact on quality of life
(Myrseth et al., 2006). However, vestibular dysfunction per-
sists frequently after VS surgery (Hirvonen et al., 1995).
Central compensation occurs in most of the patients, and pa-
tients without central compensation suffer more from imbal-
ance (Abboud et al., 2016).
Hearing loss is another important symptom associated with
the operation and one of the causes of depression (Blomstedt
et al., 1996). Although hearing preservation surgery of VS has
become one of the goals during tumor resection, only 40% of
the patients in whom the cochlear nerve was left intact, pre-
served hearing. Moreover, only 9.8% of the patients had pure
tone average (PTA) hearing level better than 30 dB in the
affected side (Levo et al., 2000b). Sanna modified the Amer-
ican Academy of Otolaryngology-Head and Neck Surgery
(AAO-HNS) grading scheme to reflect more accurately what
kind of hearing is being preserved, and reported that class A or
B was obtained in 6.8% of the middle cranial fossa approach
patients and in 16.7% of the retrosigmoid approach patients,
while the figures were 32.2% and 31.3%, respectively, when
the AAO-HNS system was applied (Sanna et al., 2004). Even
contralateral hearing loss and facial paralysis have been
associated with excessive loss of cerebrospinal fluid (Lustig
et al., 1995; Shuto et al., 2011; Warade et al., 2016). New
tinnitus also appeared postoperatively in 39.8% of VS patients
(Levo et al., 2000c).
Persistent post-operative headache is an annoying compli-
cation of VS surgery especially associated with retrosigmoid
approach. The headache was investigated to be linked to
neuropathic pain, allegedly caused by trigeminal irritation of
the inner ear and the posterior fossa, which has recently been
linked to vascular pain (Levo et al., 2000a). Patients with pre-
existing headaches who were treated with microsurgery had
worse dizziness handicap inventory (DHI) total scores than
those managed with observation (wait-and-scan) or gamma
knife radiotherapy (Carlson et al., 2014).
Facial paralysis after VS resection remains a concern and
can significantly reduce QOL for patients in the postoperative
period. Especially the occurrence of delayed facial palsy,
which may appear in 29% of patients after VS operations
regardless tumor size and surgical approach, is a challenge for
both patients and surgeons. At 1 year, 97% of the patients
recovered to better than House-Brackmann grade III facial
nerve function (Lalwani et al., 1995). Patients with a gross
total tumor resection or undergoing a retrosigmoid approach
may be at higher risk of developing delayed facial paralysis
(Carlstrom et al., 2016). In the case of immediate total pa-
ralysis, no patients achieved totally normal facial function
(grade I), and only 10% recovered to a grade II (Pardo-Maza
et al., 2016).
Cerebrospinal fluid (CSF) leakage is a severe complication
associated with VS surgeries which may cause meningitis andoccur in 6.8e17% patients receiving tumor removal (Brennan
et al., 2001; Hoffman, 1994; Rodgers and Luxford, 1993). An
observation showed that CSF leakage was the cause of
admission after discharge in 3.52% (240) of 6820 patients
within 30 days, was implicated in nearly half of 490 read-
missions (48.98%) (Alattar et al., 2017).3.2. Risks and complications of radiotherapyStereotactic radiotherapy has been considered as a safe
method in the treatment of VS. However, hydrocephalus is
frequently observed in VS patients after gamma knife radio-
surgery regardless the tumor size (Bloch et al., 2003; Gardner
et al., 1954; Roche et al., 2008; Rogg et al., 2005; Steenerson
and Payne, 1992). Lee et al. fitted an optimal predictive model
and found that developing communicating hydrocephalus
following stereotactic radiotherapy was most likely if the
tumor had a volume 13.65 cm3 (Lee et al., 2016). Stereo-
tactic radiotherapy is not suitable for cystic VS and its efficacy
is significantly reduced, when the tumor is growing rapidly
(Marston et al., 2016). Stereotactic radiotherapy may cause
facial palsy and trigeminal neuropathy, which were signifi-
cantly associated with the history of prior surgical resection,
tumor size, and the peripheral tumor dose (Chihara et al.,
2007). An international cross-sectional study showed that
19.4% microsurgery-treated patients and 2% stereotactic
radiotherapy-treated patients had worsened facial nerve func-
tion, whereas none of the conservatively managed patients
experienced an objective decline in facial nerve function at the
last clinical follow-up (Tveiten et al., 2016). Hearing loss may
occur in 18% of VS patients received stereotactic radio-
therapy, and 5.8% patients developed trigeminal neuropathy
(Hempel et al., 2006).
4. Wait and scan strategy4.1. Advantages of wait and scan procedureIn 1994, Jørgensen and Pedersen reported the management
outcome in 78 patients who had been diagnosed with acoustic
neuroma over a period of 13 years. They found that among 59
patients treated with microsurgery (46 patients with trans-
labyrinthine, and 13 with suboccipital surgery), 4 died, 30 had
problems with eating, drinking and balance, 17 had severe
facial palsy, 21 discontinued their work after operation, and 30
had psychological problems. However, 19 patients (20 neu-
romas) who were kept under observation (wait and scan) had
not deteriorated medically or socially (Jorgensen and
Pedersen, 1994). Afterwards, Stangerup et al. reported hear-
ing outcomes of 1144 VS patients managed with “wait and
scan” during a 33-year period regarding the predictive value of
hearing level at diagnosis. They found that in VS patients,
good high frequency hearing and good speech discrimination
at diagnosis are useful tools in predicting good hearing after
observation (Stangerup et al., 2010). In 2015, Jufas et al. re-
ported the quality of life (QOL) among 78 cases who under-
went microsurgical excision of VSs compared with 145 cases
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scores for surgically managed versus “wait and scan” managed
VS patients are in physical role limitation and social func-
tioning. Handicap due to disequilibrium had the greatest
negative impact on QOL (Jufas et al., 2015). Kim et al. also
reported QOL in 108 patients with VSs (microsurgery in 47,
gamma-knife radiotherapy in 27, and observations in 34), and
their QOL did not differ significantly among the three groups
with respect to four of the eight domains of the questionnaires
(Kim et al., 2015).
Therefore, the “wait and scan” management of VS is a safe
method with the least problems and provides a better QOL for
the patient than active treatments.4.2. Status in the clinical application of “wait and scan”Until now, eight countries including USA, Denmark,
Finland, Italy, Australia, Norway, Netherlands, and South
Korea have reported conservative management for VS
(Table 1). USA (the Florida Ear and Sinus Center) started the
“wait-and-scan” management for VS in 1974 (Rosenberg,
2000). Denmark legislated a policy that patients in with a
unilateral cerebello-pontine angle tumor resembling a typical
VS are required to be referred for a potential primary “wait-
and-scan” management at the ENT department in Copenhagen
University Hospital, Rigshospitalet/Gentofte (Stangerup and
Caye-Thomasen, 2012). Italy reported the results of the sec-
ond largest sample size (Patnaik et al., 2015). South Korea is
the only Asian country that started the conservative manage-
ment for VS in 2012 (Kim et al., 2015).
In the report from USA, tumors with “wait and scan”
management did not grow or regressed in 42%. Surgically
treated tumors did not grow or regressed after subtotal
resection of acoustic neuroma in 68.5% of patients, and 6.1%
required revision surgery due to tumor growth or progressive
symptoms (Rosenberg, 2000). Based on the Surveillance,
Epidemiology and End Results (SEER) database, patients
who received radiation therapy were younger and had larger
tumors compared to those electing primary observation. TheTable 1
Reports on “wait-and-scan” management for vestibular schwannoma from differen
Country Authors Start year Obs period (y
USA Rosenberg 1974 17.2 (Ma)
Jethanamest et al. 2002 5.6 (Me)
Carlson et al. 2004 8
Fayad et al. 1988 4.8 (Me), 15.
Denmark Stangerup and Caye-Thomasen 1976 16 (Me)
Huang et al. 1976 9.5 (Me), 27
Finland Levo et al. 1981 20
Italy Patnaik et al. 1986 3 (Me), 13 (M
Australia Jufas et al. 1994 7.9 (Me), 17.
Norway Breivik et al. 2000 3.6 (Me), 9.6
Varughese et al. 2000 5 (Ma)
Netherlands Wolbers et al. 2000 6.2 (Me), 14
South Korea Kim et al. 2012 1 (Me & Ma
Ma: maximum observation period; Me: median time; NF-2: was neurofibromatosi
a The 2 reports in Denmark were from the same hospital.
b The 2 reports in Norway were from the same hospital.microsurgical treatment was more common in younger pa-
tients and larger tumor size categories. An equation to pre-
dict future management practices created using linear
regression predicted that by 2026, half of all cases of VS in
USA will be managed initially with observation (Carlson
et al., 2015).
In Denmark, 3.8% of 1261 sporadic VS tumors displayed
spontaneous shrinkage that started in 3.9 y after diagnosis
(Huang et al., 2013). In Finland out of 31 cases with obser-
vation, the majority of the patients could live fairly normal
lives and required no treatment (Levo et al., 1997).
In Italy that 84 (54.5%) tumors showed no growth, 12
(7.8%) showed slow growth, and 2 (1.3%) tumors showed fast
growth during the observation period of 5 years. When the
results of “wait and scan” are compared with the literature on
radiotherapy, it is possible that a portion of control of tumor by
radiotherapy could be attributed to the nature course of VS
(Patnaik et al., 2015). In Netherlands, approximately a quarter
of the patients had a low risk for growth, which was connected
to hearing loss lasting longer than 2 years and an entirely
intracanalicular location. The authors suggested that this
subgroup of patients does not need regular follow-up with the
MRI (Wolbers et al., 2016).4.3. Growth rate and transition of the management
modalityThe natural history of VS growth is intangible, in a way that
the tumor may grow continuously or only to a certain size,
followed by stagnation or even shrinkage. Progressive growth
in the cerebellopontine angle would finally lead to compres-
sion of the brainstem and/or the cerebellum, occlusion of the
fourth ventricle, and subsequently incarceration (Stangerup
and Caye-Thomasen, 2012). The VS can be defined as either
purely intrameatal or intra-extrameatal, in which tumor
extension into the cerebellopontine angle. The size of an intra-
and extrameatal tumor is determined by the largest extra-
meatal diameter, excluding the intrameatal portion (Kanzaki
et al., 2003). However, purely extrameatal VSs were veryt countries.
) Cases NF-2 Reference
70 excluded (Rosenberg, 2000)
94 excluded (Jethanamest et al., 2015)
238 unknown (Carlson et al., 2015)
6 (Ma) 114 excluded (Fayad et al., 2014)
2500 excluded (Stangerup and Caye-Thomasen, 2012)a
(Ma) 1261 excluded (Huang et al., 2013)a
31 included (Levo et al., 1997)
a) 576 excluded (Patnaik et al., 2015)
8 (Ma) 145 excluded (Jufas et al., 2015)
(Ma) 193 excluded (Breivik et al., 2012)b
355 excluded (Varughese et al., 2012)b
(Ma) 155 excluded (Wolbers et al., 2016)
) 34 unknown (Kim et al., 2015)
s type 2 excluded? Obs: observation.
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Tomogane et al., 2013).
The present judgment for growth of a purely intrameatal
tumor was to measure the extrameatal extension. For intra-
and extrameatal tumors, an obvious growth was defined as an
increase of at least 3 mm in the largest extrameatal diameter,
to rule out inter-individual measuring variability and error due
to unaligned scanning images. Largest diameter measurement
was reported to be adequate when merely evaluating absolute
growth (Rosenberg, 2000; Walsh et al., 2000).
Various growth rates were reported by different research
groups. In general, VSs grow very slowly but varies in in-
dividuals with the annual tumor growth rate varying from
0.4 mm/y to 2.9 mm/y (Yoshimoto, 2005). Even spontaneous
shrinkage was observed in 3.8% of tumors, and relative
shrinkage was significantly greater for pure intrameatal tumors
at diagnosis, compared to intra- and extra-meatal tumors (Huang
et al., 2013). Fayad et al. found that 38% of tumors grew with an
average of 6.5mm during the period of 4.8 years at a mean value
of 3.1 mm/y (Fayad et al., 2014). Patnaik et al. reported a growth
rate of 1.2± 2.2 mm/y. Themean growth ratewas 1.1± 2.2mm/
y in intrameatal tumors and 1.4 ± 2.2 mm/y in extrameatal tu-
mors did not differ significantly. The mean growth rate of cystic
tumors was 6.1 ± 3.1 mm/y. The mean growth in patients
younger than 40 years was 2.6 ± 3.8 mm, which was faster than
that of patients older than 40 years (1.2 ± 2.6 mm).
Varughese et al. compared the growth dynamics of VS
patients managed by “wait-and-scan” using a mm/y-based
model, a cm3/y-based model, and a volume doubling time
(VDT)-based model. They found that VDT displayed a mean
growth rate of 4.4 years (95% CI 3.5e6.0). A cutoff time of
5.2 y provided the best value to distinguish growing from non-
growing tumors (Varughese et al., 2012).
How to decide a transition of the management modality
from “wait-and-scan”? In general, if significant growth occurs,
active treatment is an option. However, some old patients may
remain “wait-and-scan” even with obvious growth, and sur-
gery might be performed in patients with stable and small
tumors who would insist on primary operation (Stangerup and
Caye-Thomasen, 2012).
Active treatment of tumors larger than 15 mm has been sug-
gested, since further growth of the tumor was associated with an
increase in operative complications, such as facial paralysis (Tos
et al., 1998). Hearing preservation surgery for VS has been
intended for more than 40 years (Cohen and Ransohoff, 1984;
Wade and House, 1984), and this may influence on treatment
decision since preserving hearing is more challenging in surgery
of large VS. Sanna et al. reported that hearing preservation in VS
is a more difficult proposition than most surgeons appreciate,
especially in terms of serviceable hearing (Sanna et al., 2004).
Levo et al. has reported that hearing was preserved in 40% of
operated patients and, subjectively, the preserved hearing was
useful in understanding of speech in 62% of the patients (Levo
et al., 2002). These figures may be changing in the future due
to increased amount of patients with wait and scan strategy.
It has been published that a VS tumor may grow first and
then shrink, and the ‘wait and scan’ strategy might be appliedin VS patients with a largest extrameatal diameter of up to
20 mm (Huang et al., 2013). For example, one of our patients
with VS larger than 15 mm had normal facial nerve function
and excellent hearing 6 months after tumor removal through
retro-sigmoid approach. Perioperative real time auditory
brainstem response monitoring demonstrated preserved func-
tion after tumor removal (Figs. 1 and 2). This suggests that
individual treatment planning is applicable.
5. Contrast MRI
Gadolinium-contrasted MRI has been a standard protocol
in diagnosing and following-up VS for decades (Kingsley
et al., 1985). Gadolinium-contrast MRI detects VS by
demonstrating the uptake of the contrast agent in the tumor
through an impaired vasculature barrier resulted from the
active angiogenesis of the tumor (Caye-Thomasen et al.,
2005; de Vries et al., 2013; Koutsimpelas et al., 2007).
However, application of gadolinium-chelate in MRI in-
creases the cost and raises a toxicity issue. The typical
toxicity includes cellular impairment by dissociated gado-
linium, zinc deficiency, and nephrogenic systemic fibrosis.
Replacement of Gd3þ within the chelate molecule by body
cations leads to free Gd3þ release and formation of zinc-
chelate that causes zinc deficiency (Idee et al., 2006;
Laurent et al., 2001). The released Gd3þ may cause neph-
rogenic systemic fibrosis when the patient has a low renal
clearance (Tervahartiala et al., 1991; Thakral et al., 2007;
Thomsen, 2004). If patients need multiple scans, the risk of
causing nephrogenic systemic fibrosis is higher due to the
precipitation with tissue anions in the bone that serves as a
site for gadolinium storage (Thakral et al., 2007). This is a
critical issue in VS patients with “wait-and-scan” manage-
ment who needs multiple scans to follow the tumor growth.
Therefore, it has been important to develop non-contrast MRI
to follow tumor growth in VS patients.
6. Non-contrast MRI6.1. Sequences of non-contrast MRI
6.1.1. T2-weighted fast spin echo
The 8th cranial nerve is surrounded by cerebrospinal fluid
(CSF) which provides a natural contrast for MRI. Therefore,
any internal acoustic meatus (IAM) masses will squeeze the
adjacent CSF away and produce a hypointense area on T2-
weighted MRI. In 1996, Fukui et al. reported the T2-
weighted MR characteristics of IAM masses and found that
all 50 masses were hypointense relative to CSF on fast spin
echo (FSE) images using contrast-enhanced T1-weighted
MRI as a reference (Fukui et al., 1996). Five of the 8 small
lesions ranged in maximum diameters from 3 to 4 mm were
identified with confidence. Even the remaining three smaller
(2  2 mm; 3  3 mm; 3  4 mm) lesions displayed
hypointense signal when reviewed retrospectively (Fukui
et al., 1996). In another observation on 25 patients and 25
control subjects, there was no significant difference between
Fig. 1. Real time ABR monitoring of a VS patient (extrameatal diameter of tumor 19 mm) during operation using ISIS IOM system (Inomed, Emmendingen,
Germany). A 31 years old man suffered from colitis ulcerosa and was treated with Asacol 800 mg 1  2. The patient complained of 2 years hearing loss, tinnitus
and imbalance, some vertigo attacks, and MRI revealed abovementioned tumor. Video head impulse test was normal in each horizontal, left anterior-right posterior
(LARP) canals or right anterior-left posterior (RALP) canals planes. The ABR on the ipsilateral (Ips) side (B, D) demonstrated even increased amplitude at
waveforms I and III immediately after tumor removal comparing to the contralateral (Contr) side (A, C). Post: post-removal; Pre: pre-removal.
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conventional spin-echo imaging in detection of VSs
although 2 lesions measuring <5 mm were missed (Allen
et al., 1996).
6.1.2. Sampling perfection with application-optimized
contrasts by using flip angle evolution
The sampling perfection with application-optimized con-
trasts by using flip angle evolution (SPACE) sequence is a
proprietary 3D-FSE sequence and is analogous to the VISTA
(volume isotropic turbo spin-echo acquisition [Philips
Healthcare, Best, the Netherlands]) sequence or Cube
sequence (GE Healthcare, Wisconsin, USA) (Mugler, 2014).
Recently, Chokshi et al. evaluated cervical spinal MRI anat-
omy using SPACE sequence, and found that T2-SPACE mayFig. 2. Audiogram of a VS patient before and 6 months after near total VS resecti
audiogram was normal, speech discrimination scores 100%, and speech threshold 0/
of 18 dB, speech discrimination of 100%, and speech threshold of 10 dB (B). AC-
bone conduction of the right ear.be equivalent or superior to T2-FSE for the evaluation of
cervical spine anatomic structures, and T2-SPACE showed a
lower degree of CSF pulsation artifact than did the T2-FSE
(Chokshi et al., 2017).
6.1.3. 3D constructive interference in the steady state
3D constructive interference in the steady state (CISS) has
the advantages of fast acquisition, high spatial resolution, and
high contrast-to-noise ratio compared to with 3D T2-weighted
MRI (Lane et al., 2004). Casselman et al. reported the first
study on imaging the inner ear, cerebellopontine angle, and VSs
using CISS sequence as early as 1993 (Casselman et al., 1993).
Using axial CISS and coronal T2-weighted FSE, Abele et al.
reported 100% sensitivity, high accuracy and specificity, and
excellent inter-observer reliability in detecting small (10 mm oron through a retrosigmoid approach. Before operation (Pre-op), the pure tone
0 dB (A). Postoperatively (Post-op) there was a mild hearing loss with the PTA
L: air conduction of the left ear; AC-R: air conduction of the right ear; BC-R:
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et al., 2014). In the follow-up imaging of VSs, CISS
sequence alone showed the sensitivity, specificity, and accuracy
for detection of progression to be 100% (Ozgen et al., 2009).
6.1.4. 3D-fast imaging employing steady state acquisition
3D-fast imaging employing steady state acquisition (3D-
FIESTA) was recently introduced, and was demonstrated to
give significantly higher spatial resolution with outstanding
image contrast between the cranial nerves and CSF and has
much shorter image acquisition time than conventional MRI
scan (Erdogan et al., 2013; Rigby, 2006). Ishikawa et al. re-
ported that 3D-FIESTA was capable of detecting the signal
intensity reduction in the inner fluids of patients with VSs in
addition to visualize the tumor itself (Ishikawa et al., 2013).
The characteristic signal changes in the inner ear fluids were
powerful enough to differentiate VSs from meningiomas.
They interpret this phenomenon as the result of elevation of
protein concentration in the inner perilymph attributed to the
blood-inner ear barrier disruption (O'Connor et al., 1981;
Silverstein, 1971). From this point of view, 3D-FIESTA
sequence seems to be superior to the CISS sequence in
depicting the pathological changes associated with VSs.
Another possibility is that the authors of using CISS sequence
did pay attention to the inner ear signal changes. Actually,
there were visible signal intensity decrease in the ipsilateral
cochlea and vestibule with lesion on the fundus of IAM, when
one carefully checks the CISS images published by the au-
thors (Abele et al., 2014). We have also used 3D-FIESTA in
studying the VS (Fig. 3). The inner ear fluids on the ipsilateral
side had lower intensities than that on the contralateral side in
non-contrast MRI using 3D-FIESTA sequence (Fig. 4).
6.1.5. Sequences for distinguishing VS from meningioma
In addition to VS, meningioma constitutes 10%e15% of
cerebellopontine angle (Nakamura et al., 2005). It is important
to distinguish VS from meningioma for both “wait-and-scan”
management and pre-operative planning due to the different
biological behavior and neurologic anatomy. The outcome withFig. 3. Comparison of non-contrast and gadolinium-contrasted MRI using a 1.5 T
operation. Both the inner ear fluids and VS was detected with high resolution in n
sequence are as following: TR 5.776 ms, TE 2.184 ms, flip angle 55, section thic
demonstrated in gadolinium-contrast MRI (B). The non-contrast and gadolinium-c
right; Vest: vestibule. Scale bar ¼ 1.0 cm.preservation of hearing is significantly better with meningioma
than VS (Nakamura et al., 2005). Tumor location is insufficient
to distinguish between these two type of tumors because a
meningioma may extend to the internal auditory meatus and a
VS may appear as pure extrameatal mass (Nakamura et al.,
2005; Tomogane et al., 2013). It was reported that approxi-
mately 25% of cerebellopontine angle meningiomas were
misdiagnosed as VSs (Grey et al., 1996). Microhemorrhage was
reportedly a characteristic phenomenon of VS attributed to the
expression of thrombomodulin in the endothelial cells, which
may play a dominant role in the development of cystic changes
in VS (Park et al., 2006; Yamahata et al., 2013). T2*-weighted
gradient-echo imaging has been used to detect intratumor
microhemorrhage in VS that did not appear in meningioma. It
had a sensitivity of 93.8%, specificity and positive predictive
value of 100%, and negative predictive value of 83.3%. How-
ever, the sample size in that study was rather small (Thamburaj
et al., 2008). The principles of echo shifting using a train of
observations (PRESTO) MRI was demonstrated to be capable
of measuring changes in microscopic magnetic susceptibility
effects caused by changes in the amount of paramagnetic
deoxyhemoglobin with significantly reduced imaging time (Liu
et al., 1993). In addition to all VS, PRESTO MRI revealed
spotty signal voids in meningioma suggesting either hemosid-
erin deposits, or microhemorrhages, or abnormal vessels
(Tomogane et al., 2013). Therefore, microhemorrhage is not an
absolute specific sign of VS although it appeared more
frequently in VS than meningiomas.6.2. Accuracy and sensitivity of non-contrast MRIFortnum et al. reviewed the literature during 1998e2008,
and concluded that the specificity of T2WI and T2*WI se-
quences ranged from 90% to 100% and from 86% to 99%
respectively (Fortnum et al., 2009). Afterwards, Abele et al.
reported that the accuracy, specificity, and sensitivity for axial
CISS alone in detecting VSs were 94%, 92%e96%, and
91%e100% respectively. The data for the coronal T2WI
sequence only were 94%e99%, 96%e100%, and 91%e96%machine at a plane showing the maximum diameter of VS in a patient before
on-contrast MRI using 3D-FIESTA sequence (A). Parameters of 3D-FIESTA
kness 0.5 mm, matrix 512  512  512. VS but not the inner ear fluids was
ontrasted MRI detected the tumor at a similar size. Coch: cochlea; L: left; R:
Fig. 4. Comparison of signal intensities in the inner ear fluids between the ipsilateral and contralateral sides in a VS patient before operation. The signal intensities
measured in the region of interests using ImageJ 1.50i (NIH, Maryland, USA) were as following: CI-1 ¼ 107; CI-2 ¼ 109; VI ¼ 114; CC-1 ¼ 120; CC-2 ¼ 140;
VC ¼ 152. B and C are enlarged windows of the right (R) (B) and left (L) (C) sides of the original image (A). CC-1: cochlear region 1 of the contralateral side; CC-
2: cochlear region 2 of the contralateral side; CI-1: cochlear region 1 of the ipsilateral side; CI-2: cochlear region 2 of the ipsilateral side; T: tumor; VC: vestibule of
the contralateral side; VI: vestibule of the ipsilateral side. Scale bar ¼ 1.0 cm.
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data were 97%e99%, 96%e98%, and 100% respectively
(Abele et al., 2014).6.3. Advantages and clinical relevance of non-contrast
MRI in vestibular schwannoma imagingNon-contrast MRI of vestibular schwannoma has no risk of
causing zinc deficiency, skin ulceration, testicular atrophy, and
nephrogenic systemic fibrosis connected to the use of
gadolinium-chelate (Idee et al., 2006; Tervahartiala et al.,
1991; Thakral et al., 2007; Thomsen, 2004). In general, non-
contrast MRI is faster, cheaper, and safer than the contrast
MRI. Attributing to the accuracy, specificity, and sensitivity,
non-contrast MRI can replace the contrast MRI in VS
imaging.
7. Conclusions
VSs may grow continuously or only to a certain size, fol-
lowed by stagnation or even shrinkage. In general, the tumors
grow slowly and “wait-and-scan” management is suitable for
up to 87% of VSs. When the tumor demonstrates a greater
than 2 mm linear difference in any plane between the diag-
nostic MRI scan and the last available scan, the tumor can be
considered growing. Taken account the tumor size and other
clinical factors the wait-and-scan management can be
continued or either microsurgery or stereotactic radiotherapy
can be considered. However, stereotactic radiotherapy is un-
suitable for cystic VS and the efficacy significantly reducedwhen the tumor is growing rapidly. Detailed non-contrast MRI
has the potential to replace contrast MRI in diagnosing and
following growth of VSs in the future (Abele et al., 2014;
Allen et al., 1996; Fortnum et al., 2009; Fukui et al., 1996;
Ozgen et al., 2009). Specific sequences of non-contrast MRI
may be used to distinguish VSs from meningiomas.
8. Future perspectives of wait-and-scan management and
non-contrast MRI
“Wait-and-scan” strategy in VS management should be
included in the routine treatment options of VS. A protocol of
non-contrast MRI in diagnosing and following VS reduces the
risks for complications related to the use of gadolinium.
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